Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses

Sedegah, Martha, Rogers, William O., Belmonte, Maria, Belmonte, Arnel, Banania, Glenna, Patterson, Noelle B., Rusalov, Denis, Ferrari, Marilyn, Richie, Thomas L., and Doolan, Denise L. (2010) Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine, 28 (17). pp. 3055-3065.

[img] PDF (Published Version) - Published Version
Restricted to Repository staff only

View at Publisher Website: http://dx.doi.org/10.1016/j.vaccine.2009...
 
5


Abstract

We previously reported the capacity of the cationic lipid-based formulation, Vaxfectin®, to enhance the immunogenicity and protective efficacy of a low dose plasmid DNA vaccine against Plasmodium yoelii malaria in mice. Here, we have extended this finding to human Plasmodium falciparum genes, evaluating the immune enhancing effect of Vaxfectin® formulation on a mixture, designated CSLAM, of five plasmid DNA vaccines encoding antigens from the sporozoite (PfCSP, PfSSP2/TRAP), intrahepatic (PfLSA1), and erythrocytic (PfAMA1, PfMSP1) life cycle stages of P. falciparum administered at 2, 10 or 50 μg doses. Vaxfectin® formulation enhanced both antibody and cellular immune responses to each component of the multi-antigen vaccine mixture, as assessed by ELISA, IFAT, and IFN-γ ELIspot, respectively. There was no apparent antigenic competition, as indicated by comparison of responses induced in mice immunized with PfCSP vs. CSLAM. These data showing that Vaxfectin® can enhance the immunogenicity of plasmid DNA vaccines administered at low doses per body weight, and in combinations, has important clinical implications for the development of a vaccine against malaria, as well as against other public health threats.

Item ID: 42729
Item Type: Article (Refereed Research - C1)
Keywords: malaria; T cells; multi-gene; plasmid DNA vaccines; immune enhancement
ISSN: 1873-2518
Funders: United States Army Medical Research and Materiel Command (USAMRMC), Naval Medical Research Centre (NMRC)
Projects and Grants: USAMRMC 61153NM458.S18.A0242
Date Deposited: 22 Mar 2016 00:59
FoR Codes: 11 MEDICAL AND HEALTH SCIENCES > 1107 Immunology > 110799 Immunology not elsewhere classified @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 100%
Downloads: Total: 5
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page